Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Homann

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2008
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische OnkologieS-E Al-Batran, J T Hartmann, R Hofheinz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2018
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicityR-D Hofheinz, S Lorenzen, J Trojan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trialM R Gaiser, S Lorenzen, K Merx, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2008
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische OnkologieS-E Al-Batran, J T Hartmann, R Hofheinz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2018
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicityR-D Hofheinz, S Lorenzen, J Trojan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 12, 2018
Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trialM R Gaiser, S Lorenzen, K Merx, et al.
Pageof 6